Biotech Startups

ExploraMed is a medical device incubator that develops new med tech companies and products from early-stage concept through development. Its portfolio includes ventures such as Revelle Aesthetics, an aesthetics medical device company acquired by Tiger Aesthetics in 2024.

1 investor

Exploristics is a biostatistics and data science company providing clinical trial design, simulation, and statistical consulting for drug development sponsors. It has joined MMS and offers the KerusCloud trial simulation platform to help sponsors model trial scenarios and improve regulatory success.

1 investor

Exposome researches how environmental factors affect human health and develops products through its formulations and application lab, supported by its own manufacturing facility. The company operates in the health and wellness space with in-house product development and production.

1 investor

Exprimary develops bioanalytical instrumentation and assay products at reduced cost for research and diagnostic markets. The company focuses on enabling personalized healthcare by improving access to bioanalysis tools globally.

1 investor

Externa develops biologics using genetic code expansion, a technology aimed at incorporating synthetic amino acids into proteins of any type and size. The company positions its platform for partnerships in protein and biologics development.

1 investor

Extractas Bioscience is an integrated agricultural research and manufacturing company that grows poppy crops and performs botanical extraction, offering alkaloid raw materials and active pharmaceutical ingredients. It provides field-to-finished-goods services spanning agricultural, analytical, and manufacturing operations, including custom botanical extraction and synthetic manufacturing.

1 investor

Exubrion Therapeutics develops veterinary therapies using conversion electron therapy from Tin-117m to treat pain and inflammation in companion animals. Its initial product, Synovetin OA, is a minimally invasive intra-articular injection for canine elbow osteoarthritis, marketed to veterinarians and pet owners.

1 investor

EyeD Pharma develops pharmaceutical treatments focused on ophthalmology, particularly for glaucoma and related eye conditions. The company serves ophthalmologists and eye care professionals in treating patients with vision-related diseases.

1 investor

Eyestem is a cell therapy company developing a scalable platform for treating incurable diseases, with embedded manufacturing and quality processes. Its lead product, Eyecyte-RPE, is an RPE cell therapy for Dry Age-related Macular Degeneration (AMD) currently in a Phase 2 clinical trial.

1 investor

Eyexora is a pharmaceutical company focused on ophthalmology and eye care treatments, serving patients and healthcare providers in the therapeutic and biologics space. The company develops and commercializes therapies for conditions including glaucoma and geographic atrophy.

1 investor

Eywa Pharma develops and manufactures generic drugs across multiple therapeutic areas and dosage forms, including tablets, capsules, and oral suspensions, for patients and pharmacies. It sells products under the Eywa label in the U.S. and the Zista name in the UK, with development in Chennai, India and manufacturing in Cranbury, New Jersey.

1 investor

FREST is a Japanese biotech venture developing RNA editing technology (RNA editing nucleic acids) that edits gene structure at the mRNA level to create nucleic acid drugs for genetic and currently untreatable diseases. The company partners with medical professionals, researchers, and pharmaceutical companies to apply this drug discovery technology.

1 investor

Farment Bio Solutions develops fermentation-based biological products that increase nutrient availability in soil and reduce farmers' reliance on chemical fertilizers. The company serves agricultural producers seeking sustainable, cost-effective alternatives to conventional farming inputs.

1 investor

FATRO is an Italian veterinary pharmaceutical company that researches, develops, and manufactures animal-health drugs and vaccines, along with feed additives and medicated premixes. Founded in 1947 and based in Bologna, it serves veterinarians and the livestock and companion-animal sectors, exporting its products to over 90 countries.

1 investor

FBB Biomed builds an analytics platform that uses blood RNA-seq data to quantify gene activity across the biological systems involved in a patient's chronic disease. It serves diagnostic labs offering RNA-based monitoring tests and biopharma companies stratifying trial participants and measuring individual treatment response.

1 investor

Fennec Pharmaceuticals develops treatments for cisplatin-induced hearing loss, a side effect of cancer chemotherapy. The company serves cancer patients undergoing treatment with cisplatin-based drugs.

1 investor

FermBox is a synthetic biology research and manufacturing company that develops and commercializes bio-based products made through microbial fermentation, serving industries including textiles, cosmetics, and chemicals by replacing petrochemical and animal-based ingredients with sustainable alternatives.

1 investor

Ferric Contrast develops iron-based MRI contrast agents intended to produce high-quality magnetic resonance images of the brain, vasculature, liver, kidneys, and cancer-related tumors. The company positions its agents as safer diagnostic tools for use by physicians.

1 investor

Ferrosan Medical Devices manufactures medical devices used in surgical procedures with a focus on product quality, safety, and improved surgical outcomes. The company operates with sustainability commitments across environmental, social, and governance areas, including renewable energy use and emission reduction targets.

1 investor

Ferryx develops next-generation probiotics aimed at improving gut health for people experiencing active flare-ups of gut conditions. A 2019 spin-out from the University of Bristol, the company works to bring these probiotics into commercial production.

1 investor

Fertiga is a biotech company that develops diagnostic tools to improve IVF success rates. The company's Aurora niPCT™ is a non-invasive diagnostic tool designed to identify the most viable oocytes for fertility treatments, with a mission to make assisted reproduction more effective and accessible.

1 investor

Fertilis designs precision medical devices for in vitro fertilization (IVF) procedures, specifically instruments that reduce mechanical stress on embryos and reduce the technical burden on embryologists. The company develops tools to enhance embryologist expertise and improve clinical outcomes rather than replace human expertise in fertility treatment.

1 investor

Fibralign is a Stanford-spinout, commercial-stage company that develops therapeutic medical devices built on its Nanoweave collagen scaffolding technology for tissue engineering and regenerative medicine. Based in the San Francisco Bay Area, it addresses conditions linked to lymphatic impairment such as neurological disorders, heart disease, and glaucoma.

1 investor

Fibrocor Therapeutics is a drug developer building a pipeline of first-in-class therapeutics that target fibroblast activation to treat fibrotic diseases, with an initial focus on the genetic kidney diseases Alport Syndrome and Autosomal Dominant Polycystic Kidney Disease (ADPKD). It uses human biopsy transcriptomic analysis and access to a fibrosis tissue biobank of kidney, liver, and lung samples to identify disease-relevant, druggable targets.

1 investor